Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Summary

Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach, and is the fifth most common cancer globally. Due to its indolent nature it is difficult to treat until it’s more advanced stages and as a result remains one of the most common causes of cancer-related deaths worldwide. The incidence rate of gastric carcinoma is high in East Asia – particularly China and Japan – compared with Western markets. There are many types of gastric cancer, but adenocarcinoma is the most common type, and is diagnosed in 95% of cases.

The Asia-Pacific (APAC) gastric cancer market is forecast to grow from $1.3 billion in 2015 to $2.7 billion in 2022, at a Compound Annual Growth Rate (CAGR) of 11.4%. Gastric cancer is often a neglected cancer, as it tends to develop slowly over many years. The majority of gastric cancer cases are diagnosed in the later stages in the countries focused on in this report, with the exception of Japan, where the majority of cases are diagnosed at the early stages. The high number of cases diagnosed at stage I in Japan can be attributed to the country’s increased levels of awareness and screening for gastric cancer (Orditura et al., 2014).

As per Gayathri Kanika, GBI Research, states: “In line with improved diagnosis rates, the anticipated approval of various monoclonal antibodies (mAbs) over the forecast period will drive treatment rates across all lines of therapy and generate higher sales in the gastric cancer market”.

The current treatment landscape of gastric cancer largely comprises generic chemotherapies. However, chemotherapy provides limited clinical benefit, while causing serious side effects. Herceptin (trastuzumab) is the only marketed targeted therapy, and serves as the standard-of-care first-line treatment for HER2-positive patients – HER2-negative gastric cancer patients still receive chemotherapy regimens as the first-line treatment.

The report “Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies” provides an introduction to gastric cancer, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognoses for patients. An analysis of current treatment algorithms and options are also included.

In depth, this report provides the following analysis -
- Detailed analysis of the drugs currently marketed for this indication: trastuzumab, ramucirumab, apatinib, nab-paclitaxel and TS-1. It analyzes key characteristics, covering safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, prices and overall competitive strength. The products are also compared in a comprehensive heat map.
- Analysis of the pipeline for gastric cancer, by stage of development, molecule type, program type, mechanism of action and molecular target.
- Analysis of recent clinical trials in this indication, by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
- Supplies forecasts for the gastric cancer market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015–2022 period. The five APAC markets are covered, and data is presented at a country level.
- Provides detailed analysis of key market drivers and barriers for the gastric cancer market.
- Describes the major deals that have taken place in the global gastric cancer market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.

Scope

The Asia-Pacific gastric cancer market is forecast to grow at a compound annual growth rate of 11.4% from $1.3 billion in 2015 to $2.7 billion in 2022.
- How will angiogenesis inhibitors contribute to growth?
- What effect will the patent expirations of branded therapies have on market value?
The pipeline contains a range of molecule types and molecular targets, including those that are well-established in gastric cancer and novel targeted therapies.
- Which molecular targets appear most frequently in the pipeline?
- Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
- What are the most promising first-in-class targets for gastric cancer?
- Will the current first-in-class targets have broader therapeutic potential across the Asia-Pacific markets?
- Will the pipeline address unmet needs such as a lack of targeted treatments for HER2-negative gastric cancer patients?
Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that limit the uptake of premium-priced targeted therapeutics in the assessed countries?
- Which factors are most likely to drive the market in these countries?
Licensing deals are the most common form of strategic alliance in gastric cancer, with total deal values ranging from under $10m to over $200m.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict gastric cancer market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals.